CO5241354A1 - Terapia de combinacio para vhc - Google Patents

Terapia de combinacio para vhc

Info

Publication number
CO5241354A1
CO5241354A1 CO00028688A CO00028688A CO5241354A1 CO 5241354 A1 CO5241354 A1 CO 5241354A1 CO 00028688 A CO00028688 A CO 00028688A CO 00028688 A CO00028688 A CO 00028688A CO 5241354 A1 CO5241354 A1 CO 5241354A1
Authority
CO
Colombia
Prior art keywords
combination therapy
ribavirin
hcv combination
hcv
interferon
Prior art date
Application number
CO00028688A
Other languages
English (en)
Inventor
A Brass Clifford
Glude Paul W
Edward Piken
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO5241354A1 publication Critical patent/CO5241354A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen los métodos para tratar pacientes que tienen infecciones virales susceptibles, especialmente la infección por hepatitis C crónica administrando a dicho paciente una cantidad terapéuticamente efectiva de una terapia de combinación de interferón-alfa y ribavirina durante un periodo suficiente como para mejorar la hemólisis relacionada con la ribavirina.
CO00028688A 1999-04-19 2000-04-18 Terapia de combinacio para vhc CO5241354A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29468799A 1999-04-19 1999-04-19

Publications (1)

Publication Number Publication Date
CO5241354A1 true CO5241354A1 (es) 2003-01-31

Family

ID=23134504

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00028688A CO5241354A1 (es) 1999-04-19 2000-04-18 Terapia de combinacio para vhc

Country Status (14)

Country Link
EP (1) EP1046399A1 (es)
JP (1) JP2002542202A (es)
CN (1) CN1355708A (es)
AR (1) AR023541A1 (es)
AU (1) AU4463300A (es)
BR (1) BR0009840A (es)
CA (1) CA2306039A1 (es)
CO (1) CO5241354A1 (es)
HU (1) HUP0200942A3 (es)
MX (1) MXPA00003974A (es)
NO (1) NO20015059L (es)
PE (1) PE20010284A1 (es)
WO (1) WO2000062799A1 (es)
ZA (1) ZA200108571B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
PL364995A1 (en) 2000-02-18 2004-12-27 Shire Biochem Inc. Method for the treatment or prevention of flavivirus
AU2002225870B2 (en) 2000-11-03 2006-09-21 Intarcia Therapeutics, Inc. Method for short-term and long-term drug dosimetry
ITMI20011863A1 (it) * 2001-09-05 2003-03-05 Zambon Spa Associazione di farmaci contro il virus dell'influenza
WO2003024461A1 (en) * 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
US20040022873A1 (en) * 2001-11-09 2004-02-05 Guilford F. Timothy Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses
ATE353658T1 (de) * 2002-06-03 2007-03-15 Nat Health Research Institutes Behandlung von flavivirusinfizierungen
AU2003294757A1 (en) * 2002-11-29 2004-06-23 Axxima Pharmaceuticals Ag Formulations useful against hepatitis c virus infections
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2516333C (en) * 2003-02-21 2011-08-23 Mochida Pharmaceutical Co., Ltd. Drug for reducing side effects in ribavirin / interferon combination therapy
NZ545159A (en) * 2003-08-13 2009-03-31 Smith Howard J & Ass Pty Ltd Method of treating viral infections
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CN101453982B (zh) 2006-05-30 2011-05-04 精达制药公司 两件式内部通道渗透递送系统流动调节器
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
CN104323981B (zh) 2009-09-28 2019-03-12 精达制药公司 基本稳态药物递送的快速建立和/或终止
MX2020004501A (es) 2010-06-03 2021-11-09 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20130129680A1 (en) * 2011-11-23 2013-05-23 Thomas Christian Lines Method for treating hepatitis c virus infection using quercetin-containing compositions
KR20180088926A (ko) 2012-07-24 2018-08-07 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
MX2015005633A (es) 2012-11-02 2016-02-03 Pharmacyclics Inc Terapia adyuvante con inhibidores de quinasa de la familia tec.
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016196851A2 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
MX2018014016A (es) 2016-05-16 2019-08-01 Intarcia Therapeutics Inc Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5157998A (en) * 1996-11-01 1998-05-29 Thomas Najarian Methods and compositions for treatment of hepatitis c infection

Also Published As

Publication number Publication date
BR0009840A (pt) 2002-01-08
AU4463300A (en) 2000-11-02
CA2306039A1 (en) 2000-10-19
MXPA00003974A (es) 2002-03-08
WO2000062799A1 (en) 2000-10-26
CN1355708A (zh) 2002-06-26
AR023541A1 (es) 2002-09-04
NO20015059D0 (no) 2001-10-18
ZA200108571B (en) 2003-01-20
EP1046399A1 (en) 2000-10-25
HUP0200942A2 (hu) 2002-07-29
HUP0200942A3 (en) 2003-03-28
PE20010284A1 (es) 2001-03-05
NO20015059L (no) 2001-12-19
JP2002542202A (ja) 2002-12-10

Similar Documents

Publication Publication Date Title
CO5241354A1 (es) Terapia de combinacio para vhc
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
HUP0100092A2 (hu) Kombinációs terápia kimutatható HCV-RNS eradikációjára krónikus hepatitis-C fertőzött betegekben
MY133891A (en) Polyethylene glycol modified interferon therapy
DK0911033T3 (da) Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis
NO20073632L (no) Behandling av hepatitt C med interferon-beta i en asiatisk populasjon
AR023824A1 (es) Terapia de hiv combinacion de antagonista ccr5-interferon alfa pegilado.
NZ588655A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
MD1875F1 (en) Method of treatment of the acute viral hepatitis B
AR036697A1 (es) Metodo para el tratamiento de la infeccion por virus de hepatitis c en pacientes sin respuesta a tratamiento
DK1251850T3 (da) Anvendelse af et kombinationspræparat i cancerbehandling
ECSP003446A (es) Terapia de combinacion para vhc
EA200501569A1 (ru) Лечение или профилактика респираторных вирусных инфекций с использованием пептидов альфа-тимозина
CO5170412A1 (es) Tratamiento del carcinoma de celula renal
WO2005058237A3 (en) Treatment of aids
CO5160259A1 (es) Interferon alfa pegilado en la terapia contra el hiv
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
DK1311279T3 (da) Behandling af hepatitis C med thymosin, interferon og ribavirin
DK1150981T3 (da) Terapeutisk necleosidforbindelse
TH46769A (th) การรักษาร่วมของ hcv
DK1311286T3 (da) Behandling af hepatitis C med thymosin og pegyleret interferon
ECSP003373A (es) Terapia contra el hiv
TH53874A3 (th) การบำบัดรักษา hcv แบบผสมผสานโดยการเหนี่ยวนำด้วยไรบาไวรินและอินเทอฟีรอนอัลฟาชนิดเพกิเลเตด
TH54147B (th) ไมโคฟิโนเลท โมฟิทิล โนการเข้าร่วมกับ PEG-IFN -a

Legal Events

Date Code Title Description
FC Application refused